Hydrogel for reducing immune-related adverse events during immunotherapy

Jeremiah Johnson with Sachin Bhagchandani & Farrukh Vohidov

Cancer treatments, especially new immunotherapies, but also traditional chemotherapy, have adverse immune side effects. To reduce the side effects of immunotherapy and other cancer treatments, we have developed a hydrogel-based technology that provides controlled intra-tumoral delivery of immunomodulators. Our technology will be able to augment the therapeutic efficacy of combination immunotherapies as well as significantly reduce systemic toxicities.  

See Sachin Bhagchandani present their project at IdeaStream 2020 below.